Funded Startups in Misgav
Misgav deals skew heavily toward large, disclosed medical rounds, with one standout: Vensica Medical’s $11M on 2024-10-28 sits far above the rest of the di…
Misgav deals skew heavily toward large, disclosed medical rounds, with one standout: Vensica Medical’s $11M on 2024-10-28 sits far above the rest of the disclosed amounts in this view, which range from $590K (Trendlines Group on 2024-11-19) up to $17M (Vessi Medical on 2024-02-14). The sector split is also concentrated: Health Care appears in 4 of 9 entries (Arcuro Medical, Trendlines Group, Vensica Medical, Escala Medical), while Biotechnology shows up in 3 of 9 entries (Vessi Medical, Biond Biologics, ViAqua Therapeutics), with Agriculture and Farming in 2 of 9 (Trendlines Group, AgroScout). Date-wise, the latest entry is Arcuro Medical on 2025-01-06, while the oldest disclosed round shown is ViAqua Therapeutics on 2021-06-09. Most “Series” labels are not uniformly specified: 2 of 9 entries are explicitly “undisclosed,” and 5 of 9 use “Series Unknown.”
Most recent rounds
9 shownRelated listings
Frequently asked
What are the largest disclosed rounds in Misgav, and do they look like outliers versus the rest?
The largest disclosed amount shown is Vessi Medical at $17M (2024-02-14). Next-largest disclosed is Vensica Medical at $11M (2024-10-28), followed by Biond Biologics at $15M (2021-11-03), while the remaining disclosed rounds cluster below $8M (e.g., AgroScout $8M on 2021-08-04 and Trendlines Group $590K on 2024-11-19).
Are Misgav rounds concentrated into a specific recent time window?
Yes, there is a clear run of activity from late 2023 through 2024: Escala Medical ($6M, 2023-06-26) leads into Vessi Medical ($17M, 2024-02-14), Vensica Medical ($11M, 2024-10-28), and Trendlines Group ($590K, 2024-11-19), culminating with Arcuro Medical on 2025-01-06 (undisclosed).
Does the sector mix in this Misgav slice skew toward one vertical?
Health Care dominates by count with 4 of 9 entries (Arcuro Medical, Trendlines Group, Vensica Medical, Escala Medical), while Biotechnology is next at 3 of 9 (Vessi Medical, Biond Biologics, ViAqua Therapeutics). Agriculture and Farming is comparatively smaller at 2 of 9 (Trendlines Group and AgroScout).
What does the stage labeling suggest: are rounds mostly specified or mostly unknown?
Stage detail is limited: 5 of 9 entries use “Series Unknown,” and 1 of 9 is explicitly “undisclosed” (Arcuro Medical on 2025-01-06). Only a minority have clearly named stages in this view, such as Series A entries like Vessi Medical ($17M, 2024-02-14) and Series C for Biond Biologics ($15M, 2021-11-03).
Which entries are worth extra scrutiny because their disclosed amounts sit at the extremes?
The low extreme is Trendlines Group at $590K (2024-11-19), which is far below the other disclosed figures like Vensica Medical’s $11M (2024-10-28) and Vessi Medical’s $17M (2024-02-14). The high end is also reinforced by Vessi Medical ($17M, 2024-02-14) and Biond Biologics ($15M, 2021-11-03), both materially above the remaining mid-single- to low-single-digit rounds.
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.